Low-dose trofosfamide plus rituximab is an effective and safe treatment for diffuse large B-cell lymphoma of the elderly: a single center experience
Schelker, Roland Christian, Herr, Wolfgang, Reichle, Albrecht and Vogelhuber, Martin (2018) Low-dose trofosfamide plus rituximab is an effective and safe treatment for diffuse large B-cell lymphoma of the elderly: a single center experience. BMC Cancer 18 (1).Date of publication of this fulltext: 28 Jul 2021 17:01
Article
Alternative links to fulltext
Involved Institutions
Details
| Item type | Article | ||||
| Journal or Publication Title | BMC Cancer | ||||
| Publisher: | BMC | ||||
|---|---|---|---|---|---|
| Place of Publication: | LONDON | ||||
| Volume: | 18 | ||||
| Number of Issue or Book Chapter: | 1 | ||||
| Date | 2018 | ||||
| Institutions | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) | ||||
| Identification Number |
| ||||
| Keywords | NON-HODGKINS-LYMPHOMA; DETUDE-DES-LYMPHOMES; PATIENTS AGED 80; PHASE-II TRIAL; CHOP CHEMOTHERAPY; PATIENTS OLDER; PALLIATIVE CHEMOTHERAPY; MAINTENANCE RITUXIMAB; RESPONSE CRITERIA; R-CHOP; Diffuse large B-cell lymphoma; Rituximab; Trofosfamide; Elderly patients | ||||
| Dewey Decimal Classification | 600 Technology > 610 Medical sciences Medicine | ||||
| Status | Published | ||||
| Refereed | Yes, this version has been refereed | ||||
| Created at the University of Regensburg | Yes | ||||
| Item ID | 46675 |
Export bibliographical data
Owner only: item control page
Altmetric
Altmetric